CB1 Receptor Activation for Sphingomyelin Storage Reduction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Dysregulation of sphingolipid metabolism leads to abnormal cellular accumulation of sphingomyelin, causing diseases such as Acid Sphingomyelinase Deficiency (ASMD) and other lysosomal storage disorders, resulting in neurological and systemic pathologies.

Innovation Solution

Increasing endocannabinoid levels and activating the CB1 cannabinoid receptor through inhibitors like FAAH to modulate sphingomyelin levels and activate neutral sphingomyelinase, thereby reducing sphingomyelin accumulation.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Quantity of substance

If acid sphingomyelinase activity is increased to degrade sphingomyelin, then sphingomyelin accumulation is reduced, but cellular toxicity from sphingomyelin breakdown products may increase

Engineering Contradiction:

Improvesphingomyelin accumulationVSAvoidcellular toxicity

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent uses CB1 receptor activation as an intermediary mechanism to indirectly reduce sphingomyelin levels. Instead of directly increasing acid sphingomyelinase activity, the invention activates CB1 receptors which then triggers downstream signaling pathways (including neutral sphingomyelinase activation) that gradually reduce sphingomyelin accumulation while avoiding the toxic effects of direct enzyme activation. This intermediary approach allows for controlled, regulated degradation.

Inventive Principle:

Principle #24Intermediary (Mediator)

Solution Approach 2:

The invention changes the regulatory parameter from direct acid sphingomyelinase activity control to CB1 receptor-mediated signaling control. By modulating endocannabinoid levels and CB1 receptor activation, the system achieves indirect control over sphingomyelin metabolism, allowing for fine-tuned regulation that prevents toxic accumulation of breakdown products while still reducing pathological sphingomyelin levels.

Inventive Principle:

Principle #35Parameter changes

2Quantity of substance

If endocannabinoid levels are increased to activate CB1 receptor, then sphingomyelin degradation is enhanced, but risk of cannabinoid side effects increases

Engineering Contradiction:

Improveendocannabinoid levelsVSAvoidcannabinoid side effects

Core Design Contradiction:

Quantity of substanceVSObject-affected harmful factors

Solution Approach 1:

The patent leverages the body's own endocannabinoid system to achieve therapeutic effects. By using endogenous cannabinoids (anandamide, 2-AG) and their metabolic pathways, the invention activates CB1 receptors through naturally occurring molecules rather than exogenous cannabinoids, thereby reducing the risk of side effects associated with synthetic or plant-derived cannabinoids while still achieving the desired sphingomyelin degradation effect.

Inventive Principle:

Principle #25Self-service

3Quantity of substance

If neutral sphingomyelinase is activated to break down sphingomyelin, then sphingomyelin levels decrease, but disruption of membrane integrity may occur

Engineering Contradiction:

Improvesphingomyelin levelsVSAvoidmembrane integrity

Core Design Contradiction:

Quantity of substanceVSStrength

Solution Approach 1:

The CB1 receptor activation creates a feedback-regulated system for sphingomyelin degradation. The endocannabinoid system naturally monitors and regulates lipid metabolism, and CB1 activation triggers controlled signaling cascades that activate neutral sphingomyelinase in a regulated manner. This feedback mechanism ensures that sphingomyelin breakdown occurs at controlled rates, preventing excessive degradation that would compromise membrane integrity while still achieving therapeutic reduction of pathological accumulation.

Inventive Principle:

Principle #23Feedback

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

Reduces sphingomyelin levels, preventing neuronal death, improving cognitive function, and extending lifespan in subjects with ASMD and related disorders.

Implementation Method 1

Increasing endocannabinoid levels and activating the CB1 cannabinoid receptor through inhibitors like FAAH

Methodology Applied

Scientific EffectEnzyme inhibition: Enzyme

Implementation Method 2

activating neutral sphingomyelinase, thereby reducing sphingomyelin accumulation

Methodology Applied

Scientific EffectEnzymatic degradation: Enzyme

Data Source

PatentUS12485117B2Compositions and methods for activating signaling through the CB1 cannabinoid receptor for treating and preventing diseases and disorders characterized by abnormal cellular accumulation of sphingolipids such as sphingomyelin

Publication Date: 2025.12.02 WYLDER NATION FOUNDATION

AI summary

The present invention provides, inter alia, compositions and methods for using CB1 cannabinoid receptor agonists, or other compounds capable of increasing endocannabinoids or endocannabinoid signaling, for treating and preventing lysosomal storage disorders in which lipid storage occurs (including, e.g., disorders associated with sphingomyelin accumulation). In particular embodiments, the present invention provides compositions and methods for treating such lysosomal storage disorders with one or more fatty acid amide hydrolase inhibitor alone or in combination with one or more additional agent.